JP6632607B2 - 抗微生物免疫修飾 - Google Patents

抗微生物免疫修飾 Download PDF

Info

Publication number
JP6632607B2
JP6632607B2 JP2017508718A JP2017508718A JP6632607B2 JP 6632607 B2 JP6632607 B2 JP 6632607B2 JP 2017508718 A JP2017508718 A JP 2017508718A JP 2017508718 A JP2017508718 A JP 2017508718A JP 6632607 B2 JP6632607 B2 JP 6632607B2
Authority
JP
Japan
Prior art keywords
macrophages
cells
infection
antigenic
species
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017508718A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017514895A5 (enExample
JP2017514895A (ja
Inventor
ハロルド デイビッド ガン
ハロルド デイビッド ガン
サリム ダンジ
サリム ダンジ
デイヴィッド ダブリュー． マリンス
デイヴィッド ダブリュー． マリンス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Qu Biologics Inc
Original Assignee
Qu Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qu Biologics Inc filed Critical Qu Biologics Inc
Publication of JP2017514895A publication Critical patent/JP2017514895A/ja
Publication of JP2017514895A5 publication Critical patent/JP2017514895A5/ja
Application granted granted Critical
Publication of JP6632607B2 publication Critical patent/JP6632607B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0266—Klebsiella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2017508718A 2014-05-02 2015-05-01 抗微生物免疫修飾 Active JP6632607B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461988117P 2014-05-02 2014-05-02
US61/988,117 2014-05-02
PCT/CA2015/050377 WO2015164979A1 (en) 2014-05-02 2015-05-01 Anti-microbial immunomodulation

Publications (3)

Publication Number Publication Date
JP2017514895A JP2017514895A (ja) 2017-06-08
JP2017514895A5 JP2017514895A5 (enExample) 2018-06-14
JP6632607B2 true JP6632607B2 (ja) 2020-01-22

Family

ID=54357960

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017508718A Active JP6632607B2 (ja) 2014-05-02 2015-05-01 抗微生物免疫修飾

Country Status (8)

Country Link
US (4) US10251946B2 (enExample)
EP (1) EP3137108A4 (enExample)
JP (1) JP6632607B2 (enExample)
CN (2) CN113855791B (enExample)
AU (2) AU2015252726B2 (enExample)
CA (2) CA3254723A1 (enExample)
RU (2) RU2020120075A (enExample)
WO (1) WO2015164979A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8980279B2 (en) * 2010-07-26 2015-03-17 Qu Biologics Personalized site-specific immunomodulation
CA3254723A1 (en) * 2014-05-02 2025-04-15 Qu Biologics Inc ANTIMICROBIAL IMMUNOMODULATION
WO2017185180A1 (en) 2016-04-26 2017-11-02 Qu Biologics Inc. Therapeutically triggering an innate immune response in a target tissue
US12491153B2 (en) 2018-01-03 2025-12-09 Qu Biologics Inc. Innate targeting of adoptive cellular therapies
US20210353693A1 (en) * 2018-10-17 2021-11-18 SciBac Inc. Live Biotherapeutics to Treat and Prevent Lung Conditions
AU2021252164A1 (en) 2020-04-09 2022-12-15 Finncure Oy Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses
US12194157B2 (en) 2020-04-09 2025-01-14 Finncure Oy Carrier for targeted delivery to a host
US20230364162A1 (en) * 2020-09-28 2023-11-16 The Regents Of The University Of Michigan Methods and compositions for intestinal inflammation

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3928565A (en) 1971-10-19 1975-12-23 Yuzuru Homma Pharmaceutical preparation of pseudomonas aeruginosa bacterial component possessing anti-tumor and anti-infection properties
JPS5946493B2 (ja) 1978-03-31 1984-11-13 株式会社三和化学研究所 異種死菌体混合物を有効成分とする抗腫瘍剤
JPS568320A (en) 1979-07-04 1981-01-28 Chisato Maruyama Drug for tumor immunotherapy comprising lipopolysaccharide as active constituent
JPS56108716A (en) 1980-01-30 1981-08-28 Sanwa Kagaku Kenkyusho:Kk Antiviral agent containing different kind dead cell mixture as effective component
JPS5839624A (ja) 1981-09-02 1983-03-08 Meiji Seika Kaisha Ltd 抗腫瘍剤
JPS6012071A (ja) 1983-06-30 1985-01-22 東レ株式会社 抗腫瘍作用を有する体液処理剤
US4880626A (en) 1985-01-18 1989-11-14 Mcmichael John Immunotherapeutic methods and compositions for the treatment of diseases of viral origin, including acquired immune deficiency syndrome
US5292513A (en) 1992-05-18 1994-03-08 Anthony G. Gristina Method for nonspecific cellular immune stimulation
US5652332A (en) 1993-03-12 1997-07-29 Xoma Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
GB9406301D0 (en) 1994-03-30 1994-05-25 Univ London Immunotherapeutic agent and its use
US6902743B1 (en) 1995-05-22 2005-06-07 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix
US5869057A (en) 1995-06-07 1999-02-09 Rock; Edwin P. Recombinant vaccines to break self-tolerance
WO1997036614A1 (en) 1996-03-29 1997-10-09 Terman David S Polymerized staphylococcal protein a for treatment of diseases
US6348586B1 (en) 1996-07-25 2002-02-19 The Trustees Of Columbia University In The City Of New York Unique associated Kaposi's sarcoma virus sequences and uses thereof
US20020128240A1 (en) 1996-12-30 2002-09-12 Bone Care International, Inc. Treatment of hyperproliferative diseases using active vitamin D analogues
US6028060A (en) 1997-01-29 2000-02-22 Vanderbilt University Treatment of chronic inflammatory diseases with CM101/GBS toxin
EP2340840B1 (en) 1998-03-27 2012-08-29 Oregon Health Sciences University Pulse dose Vitamin D drug for the treatment of hyperproliferative skin diseases
WO2001056387A1 (en) 2000-02-01 2001-08-09 Donnell Michael A O Immunotherapeutic treatment methodology for patients afflicted with superficial bladder cancer who previously failed at least one immunostimulatory therapeutic treatment regimen
US20020044948A1 (en) 2000-03-15 2002-04-18 Samir Khleif Methods and compositions for co-stimulation of immunological responses to peptide antigens
AUPQ761200A0 (en) * 2000-05-19 2000-06-15 Hunter Immunology Limited Compositions and methods for treatment of mucosal infections
TWI306760B (en) 2000-08-07 2009-03-01 Abbott Lab Use of an endothelin et-a receptor antagonist and orally delivered pharmaceutical composition comprising the same
US7118740B1 (en) 2000-09-22 2006-10-10 Mayo Foundation For Medical Education And Research Method for limiting the growth of cancer cells using an attenuated measles virus
FR2816844A1 (fr) 2000-11-17 2002-05-24 Pf Medicament Domaine periplasmique d'une proteine omp d'enterobacterie et son utilisation comme porteur et/ou adjuvant
GB2370770B (en) 2001-01-03 2005-06-01 Simon Connolly Uses of Streptococcus Vaccines
FR2822071B1 (fr) 2001-03-15 2005-07-01 Pf Medicament Utilisation d'une fraction membranaire de bacteries a gram negatif pour induire la maturation des cellules dendritiques
CA2905585C (en) 2001-03-29 2020-02-18 Synergy Pharmaceuticals, Inc. Guanylate cyclase receptor agonists for the treatment and/or prevention of cancer or polyps
US7273602B2 (en) 2001-07-19 2007-09-25 Akira Hayashi Immunotherapy for humans
EP1281767A3 (en) 2001-07-31 2003-05-28 Aladar A. Szalay Light emitting microorganisms and cells for diagnosis and therapy of tumors
AU2002353366A1 (en) 2001-12-10 2003-06-23 Bakulesh Mafatlal Khamar The process of manufacturing a pharmaceutical composition useful for management of cancer
ES2345188T3 (es) 2001-12-11 2010-09-17 Institut Pasteur Preparaciones de bacterias gram positivas para el tratamiento de enfermedades que comprenden una mala regulacion inmune.
WO2003063593A1 (en) 2002-01-28 2003-08-07 Vion Pharmaceuticals, Inc. Methods for treating cancer by administering tumor-targetted bacteria and an immunomodulatory agent
JP2005531289A (ja) 2002-02-15 2005-10-20 アゲルプ ファーマ ゲーエムベーハー Ｓ．ａｕｒｅｕｓエンテロトキシンＢ由来の免疫調節ペプチド
US20060147477A1 (en) 2002-06-11 2006-07-06 Glaxo Group Limited Immunogenic compositions
JP4618970B2 (ja) 2002-08-02 2011-01-26 マルホ株式会社 肛門圧低下外用剤
IL152127A0 (en) 2002-10-06 2003-05-29 Bio Balance Corp Probiotic compositions for the treatment of inflammatory bowel disease
NZ569331A (en) 2003-01-21 2010-08-27 Yeda Res & Dev COP 1 for treatment of inflammatory bowel diseases
AR043692A1 (es) 2003-02-06 2005-08-10 Novartis Ag 2-cianopirrolopirimidinas y sus usos farmaceuticos
EP1631312B1 (en) 2003-04-23 2008-09-10 Medarex, Inc. Compositions and methods for the therapy of inflammatory bowel disease
US7413728B2 (en) 2003-11-14 2008-08-19 Ucl Biomedica Plc Immune modulator
US20050175630A1 (en) 2003-12-23 2005-08-11 Eyal Raz Immunogenic compositions and methods of use thereof
EP1586330A1 (en) 2004-04-16 2005-10-19 Georg-August-Universität Göttingen Vaccination against malignant melanoma
US9107864B2 (en) 2004-06-07 2015-08-18 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
US8501198B2 (en) * 2004-06-07 2013-08-06 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
PL1765391T3 (pl) * 2004-06-07 2013-08-30 Qu Biologics Inc Kompozycje bakteryjne do leczenia nowotworów
US8034359B2 (en) 2004-06-07 2011-10-11 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to cancers
US8029777B2 (en) 2004-08-13 2011-10-04 Marshall Barry J Helicobacter system and uses thereof
JP5234445B2 (ja) 2004-10-05 2013-07-10 源一郎 杣 薬剤
EP2040724B1 (en) 2006-05-18 2011-10-05 Biobalance Llc Biotherapeutic compositions comprising probiotic escherichia coli and metronidazole and uses thereof
EP2056864B1 (en) 2006-08-28 2013-12-11 Omnio Healer AB Candidates against infection
NZ576590A (en) 2006-10-27 2012-08-31 Qu Biolog Inc Tissue targeted antigenic activation of the immune response to treat cancers
CA2997459C (en) 2006-10-27 2020-09-22 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to cancers
JP5249326B2 (ja) 2007-07-23 2013-07-31 ワクチン リサーチ インターナショナル ピーエルシー 不活化ブドウ球菌全細胞ワクチン
WO2009021977A1 (en) 2007-08-16 2009-02-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Human specific escherichia coli strains
HUP0700552A2 (en) 2007-08-27 2009-03-30 Janos Dr Feher Method and composition inhibiting inflammation
WO2010068413A1 (en) 2008-11-25 2010-06-17 Emergent Product Development Gaithersburg Inc. Chlamydia vaccine comprising htra polypeptides
CN101954076A (zh) * 2009-04-27 2011-01-26 免疫制剂美国公司 自身免疫性肝炎的免疫疗法和预防
ES2645509T3 (es) * 2010-07-26 2017-12-05 Qu Biologics Inc Composiciones antiinflamatorias inmunogénicas
US8980279B2 (en) * 2010-07-26 2015-03-17 Qu Biologics Personalized site-specific immunomodulation
US9974848B2 (en) * 2013-11-14 2018-05-22 Duke University Tetanus toxoid and CCL3 improve DC vaccines
CA3254723A1 (en) * 2014-05-02 2025-04-15 Qu Biologics Inc ANTIMICROBIAL IMMUNOMODULATION

Also Published As

Publication number Publication date
RU2020120075A (ru) 2020-07-03
WO2015164979A1 (en) 2015-11-05
AU2020281030A1 (en) 2021-01-07
AU2015252726A1 (en) 2016-11-10
US10251946B2 (en) 2019-04-09
CA2947631A1 (en) 2015-11-05
CN106456740B (zh) 2021-06-08
US20240091330A1 (en) 2024-03-21
EP3137108A1 (en) 2017-03-08
US11819543B2 (en) 2023-11-21
US20170087237A1 (en) 2017-03-30
AU2015252726B2 (en) 2020-12-24
JP2017514895A (ja) 2017-06-08
US20190247484A1 (en) 2019-08-15
CN106456740A (zh) 2017-02-22
US10946083B2 (en) 2021-03-16
AU2020281030B2 (en) 2024-08-08
CA3254723A1 (en) 2025-04-15
RU2016147048A (ru) 2018-06-05
CN113855791B (zh) 2024-11-19
RU2016147048A3 (enExample) 2019-02-22
EP3137108A4 (en) 2017-09-27
US20210138057A1 (en) 2021-05-13
RU2724895C2 (ru) 2020-06-26
CN113855791A (zh) 2021-12-31

Similar Documents

Publication Publication Date Title
JP6632607B2 (ja) 抗微生物免疫修飾
EP3235506B1 (en) Immunogenic anti-inflammatory compositions
CN105816865A (zh) 免疫原性抗炎组合物
JP6196677B2 (ja) 交差防御性サルモネラワクチン
JP2005519941A (ja) 結核の管理のために有用な医薬組成物の製造方法
CN101155596B (zh) 引发抗禽分枝杆菌副结核亚种的免疫应答的组合物
AU2004296394A1 (en) Orally-administered live bacterial vaccines for plague
KR20240163211A (ko) 건락성 림프절염 감염 염소로부터 분리된 신규 코리네박테리움 슈도투베르쿨로시스 균주 및 이를 포함하는 건락성 림프절염 예방용 백신 조성물
Mielke et al. 3 In Vivo Analysis: 3.1 The Immune Response in Mice Challenged with Bacterial Infections
Micu et al. Diagnosis and treatment in Helicobacter pylori infection
Inglesby III. Pneumonic Plague
Robson et al. Immunity in tuberculosis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180427

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180427

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190207

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190314

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190702

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190729

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20191111

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191210

R150 Certificate of patent or registration of utility model

Ref document number: 6632607

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250